[sci.med.aids] HICN407 News -- excerpts.

dmcanzi@watserv1.uwaterloo.ca (David Canzi) (04/15/91)

                  Medical News for March 18 to April 4, 1991
        Copyright 1991: USA TODAY/Gannett National Information Network
                          Reproduced with Permission

                                      ---
                                March 20, 1991
                                      ---

                           AZT MAKER SUED BY GROUP:

   An AIDS advocacy group, accusing the makers of the drug AZT of charging too
much,  is suing the company in an attempt to  nullify  its  patent.  In  their
lawsuit,  two HIV-infected men and the People With AIDS Health Group, New York
City,  say Burroughs Wellcome Co.'s  patent  should  be  invalid  because  the
company was not alone in developing AZT for treating AIDS in humans.

                          BURROUGHS SAYS SUIT UNFAIR:

   Burroughs  Wellcome  says  it has acknowledged other contributions in AZT's
development.  In 1987,  the Food and Drug Administration  approved  AZT  as  a
treatment  for  AIDS.  Last year,  Burroughs Wellcome sold $287 million of AZT
worldwide,  under the brand name Retrovir.  The company says  since  it  began
marketing AZT it has lowered the cost by about 70 percent to $2,000 a year.

                                      ---
                                 April 3, 1991
                                      ---

                              PREGNANT WITH AIDS:

   Up to 80,000 U.S.  women ages 15 to 44 may be infected with HIV,  the virus
that  causes  AIDS,  researchers  say  in  Wednesday's Journal of the American
Medical Association.  Government scientists looked at tests of newborns in  38
states  and  the  District  of  Columbia.  When  infants test positive for HIV
antibodies it means their mothers are infected.

                                      ---
                                 April 4, 1991
                                      ---

                           JOURNAL REPORTS ON AIDS:

   The AIDS virus enters the body like a killer lion,  but is quickly tamed by
powerful natural defense mechanisms,  two new studies show.  Identifying those
mechanisms - and understanding how the virus eventually escapes them  -  could
lead  to  vaccines  and  drugs that prevent HIV infection or stop it before it
causes AIDS, scientists report in The New England Journal of Medicine.

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
                      Center for Disease Control Reports
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

                     Morbidity and Mortality Weekly Report
                           Thursday  March 28, 1991

                                Current Trends
     Characteristics of, and HIV Infection among, Women Served by Publicly
    Funded HIV Counseling and Testing Services -- United States, 1989-1990

    In 1990,  the number of reported acquired immunodeficiency syndrome (AIDS)
cases  among  women  in the United States exceeded 15,000,  an increase of 34%
from 1989 (1).  Public health surveillance of the human immunodeficiency virus
(HIV)/AIDS  epidemic  has  included  monitoring  of  publicly funded voluntary
counseling and testing (CT) programs,  such as  the  voluntary  client  record
system  (representing  43%  of  all reported CT visits) that collects detailed
information for each CT  visit.  This  report  summarizes  findings  based  on
information  from  the  client  record system for women who received public CT
services during 1989 and 1990.
    During 1989 and 1990, women accounted for approximately 1 million (48%) of
the 2.2 million tests reported by all CT programs. Of these, 47% of tests were
from white women;  35%, black women;  and 16%, Hispanic women;  in comparison,
these groups account for 79%,  11%,  and 6%, respectively, of the U.S.  female
population  (2).  Approximately  20,000  (2%)  tests  were  positive  for  HIV
antibody,  including  0.9%  among  whites,  3.3% among blacks,  and 3.7% among
Hispanics.
    Nearly all CT visits by women  occurred  in  either  sexually  transmitted
disease (STD) clinics (29%),  HIV CT sites (29%),  or women's (family planning
and prenatal) clinics (28%).  Of seropositive tests,  40% were from CT  sites,
29%  from  STD  clinics,  and 8% from women's clinics.  Drug-treatment centers
accounted for 4% of all tests and 7%  of  all  positive  tests;  however,  the
seropositivity  rate among tests from drug-treatment centers (3.7%) was higher
than tests from other sites (CT sites, 3.0%;  STD clinics,  2.2%;  and women's
clinics, 0.7%) (Table 1).
    Most  (80%)  women  who  were  tested  did  not  report  HIV risk behavior
(including 81% of blacks, 76% of Hispanics, and 69% of whites) (Figure 1, page
203).  Of women who did not report HIV risk behavior,  1.0% were seropositive;
however,  seropositivity varied by race and ethnicity (1.9%, 1.0%, and 0.3% in
black, Hispanic, and white women,  respectively).  Of seropositive women,  65%
reported  a  specific risk behavior;  35% reported no risk behavior (22% among
whites; 24%, Hispanics; and 44%, blacks).
    Intravenous (IV)-drug use was reported by 8% of all women,  compared  with
31% of those who were seropositive. Among black, Hispanic, and white women who
identified themselves as IV-drug users,  seropositivity was 16.7%,  15.0%, and
3.8%, respectively. Of seropositive women, IV-drug use was reported by 43% and
32% of white and Hispanic women,  respectively,  compared with  26%  of  black
women.
    Women  who were sex partners of persons at risk accounted for 13% of those
tested,  but 27%  of  all  seropositive  tests  (20%,  30%,  and  40%  of  all
seropositive  black,  white,  and Hispanic women,  respectively).  The overall
seropositivity among women who were sex partners of persons at risk  was  4.3%
(1.5%, 8.2%, and 3.6% for whites, blacks, and Hispanics, respectively).

Reported by: HIV prevention programs of state and local health depts.  Program
Development/Technical Support Section, Div of STD/HIV Prevention and Office of
the Deputy Director (HIV), Center for Prevention Svcs, CDC.

Editorial  Note:  This  assessment  of  findings  at  CT sites underscores the
disproportionate impact of the HIV epidemic on  minority  populations  in  the
United  States  (1).  However,  because  these data reflect characteristics of
women who receive services  at  public  clinics  (Table  1),  they  cannot  be
considered representative of all U.S.  women.  In addition, because these data
are collected in service delivery settings,  data regarding risk may  be  less
reliable than those obtained during epidemiologic investigations, particularly
for persons who initially report no HIV risk behavior.
    Nearly half the HIV tests reported by publicly funded CT programs are from
women,  among whom blacks and Hispanics  are  disproportionately  represented.

Although  17%  of  all  women  in the United States are black or Hispanic (2),
blacks and Hispanics accounted for 73% (52% and 21%, respectively) of reported
AIDS cases among women (1).  Because of the high prevalence of  HIV  infection
and AIDS among these groups, community-based outreach programs should actively
encourage women--especially minority women--to seek HIV-prevention services.
    Sexual transmission of HIV is associated with certain STDs.  In the United
States,  syphilis incidence is 50-fold greater among black women  and  10-fold
greater  among  Hispanic  women than among white women (3).  HIV infection and
transmission have been epidemiologically linked with  genital  ulcer  disease,
including  syphilis  (3-5),  suggesting that genital ulcer disease facilitates
HIV transmission.
    Previous  documentation  of   the   association   between   syphilis   and
transmission  of  HIV (3-5) suggests that syphilis contributes to heterosexual
transmission of HIV in selected U.S. populations.  However, because many women
at risk for syphilis may not be aware of the associated risk for HIV, they may
have reported no risk behaviors during pretest  counseling.  Accordingly,  STD
and  HIV  control  programs  should  direct efforts to diagnosing and treating
women who have syphilis or who  are  reported  as  sex  partners  of  syphilis
patients (6) and should ensure that these persons receive HIV CT.
    STD  and  HIV prevention programs need to maximize the proportion of high-
risk women who receive  comprehensive  HIV  risk  assessment,  accept  pretest
counseling,  accept  HIV testing,  return for their test results,  and receive
posttest  counseling.  Based  on  the  data  in  this  report,  a  substantial
proportion  of  women who seek HIV CT services at selected public sites may be
at risk for HIV infection;  however, many of these women may be unaware of, or
unwilling to report, a specific risk behavior.  Therefore, CT sites that serve
women in areas with high prevalence of  HIV  seropositivity  should  routinely
offer all clients HIV counseling and testing.  In areas with low prevalence of
HIV seropositivity,  standardized,  thorough risk assessments  may  assist  in
identifying  a  person's risks for HIV infection,  and recommendations for HIV
testing can be made based on the results of each assessment.

References

1.  CDC.  HIV/AIDS surveillance.  Atlanta:  US Department of Health and  Human
Services, Public Health Service, January 1991:9-14.

2.   Department  of  Commerce.   Census  of  population,   general  population
characteristics,  United States summary.  Washington,  DC:  US  Department  of
Commerce, Bureau of the Census, May 1983:1-21.

3.  Rolfs RT, Nakashima AK.  Epidemiology of primary and secondary syphilis in
the United States, 1981 through 1989. JAMA;264:1432-7.

4. Cameron DW, Simonsen JN, D'Costa LJ, et al.  Female to male transmission of
human  immunodeficiency  virus type I:  risk factor for seroconversion in men.
Lancet 1989;2:403-7.

5.  Quinn TC, Cannon RO,  Glasser D,  et al.  The association of syphilis with
risk  of human immunodeficiency virus infection in patients attending sexually
transmitted disease clinics. Arch Intern Med 1990;150:1297-302.

6.  Toomey KE,  Cates W Jr.  Partner notification for the  prevention  of  HIV
infection. AIDS 1989;3(suppl 1):S57-62.

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Volume  4, Number  7                                             April  5, 1991

              +------------------------------------------------+
              !                                                !
              !              Health Info-Com Network           !
              !                    Newsletter                  !
              +------------------------------------------------+
                         Editor: David Dodell, D.M.D.
                   St. Joseph's Hospital and Medical Center
    10250 North 92nd Street, Suite 210, Scottsdale, Arizona 85258-4599 USA
                          Telephone +1 (602) 860-1121
                              FAX +1 (602) 451-1165

   Copyright 1991 - Distribution on Commercial/Pay Systems Prohibited without
                              Prior Authorization

The Health Info-Com Network Newsletter is distributed weekly.  Articles  on  a
medical  nature  are  welcomed.  If  you  have an article,  please contact the
editor for information on how to submit it.  If you are interested in  joining
the automated distribution system, please contact the editor.

E-Mail Address:
                                    Editor:
                              FidoNet = 1:114/15
                           Bitnet = ATW1H @ ASUACAD
                     Internet = ddodell@stjhmc.fidonet.org
      LISTSERV = MEDNEWS @ ASUACAD.BITNET (or internet: asuvm.inre.asu.edu)
                         anonymous ftp = vm1.nodak.edu
       (Notification List/ftp = hicn-notify-request@stjhmc.fidonet.org)

Associate Editors:

o   Dr. Bruce MacDougall, University of Massachusetts at Amherst
       (Bitnet: BRUCEMA@UMASS)
o   Dr. J. Martin Wehlou (Bitnet: WEHLOU@BGERUG51)

-- 
David Canzi		"Do not let superstition inhibit your actions."
			 -- Jeane Dixon, horoscope for Virgo, May 17, 1990.